ArticleScientific reports2026
Adipocyte-specific NR5A2 deficiency ameliorates diet-induced metabolic syndrome by suppressing adipose tissue inflammation.
Article in Scientific reports, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
4 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Obesity is a global epidemic characterized by adipose tissue dysfunction, chronic inflammation, and metabolic syndrome. The orphan nuclear receptor NR5A2 has been implicated in metabolic regulation, but its role in adipocytes remains unclear. Here, we demonstrate that NR5A2 expression is upregulated in adipose tissue of high-fat diet (HFD)-fed and genetically obese (ob/ob) mice. Adipocyte-specific NR5A2 knockout (AKO) mice exhibited resistance to HFD-induced obesity, with reduced fat mass, smaller adipocytes, and improved glucose tolerance and insulin sensitivity. Mechanistically, NR5A2 ablation attenuated adipose tissue inflammation, evidenced by decreased pro-inflammatory cytokines (IL-6, TNF-α) and macrophage infiltration, while enhancing energy expenditure and thermogenesis. Additionally, AKO mice showed reduced hepatic steatosis and improved lipid profiles. In vitro, NR5A2 deficiency impaired adipocyte differentiation and lipid accumulation. These findings identify NR5A2 as a key regulator of adipocyte hypertrophy, inflammation, and systemic metabolism, suggesting its inhibition as a potential therapeutic strategy for obesity-related metabolic disorders.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.